Loading…

Potentiation of Pirarubicin Activity in Multidrug Resistant Cells by Rifampicin

The effect of the anti-tuberculosis drug rifampicin on pirarubicin activity was investigated in multidrug-resistant cells overexpressing P-glycoprotein. Rifampicin increased the sensitivity of pirarubicin to anthracycline-resistant mouse leukemic P388 cells and significantly enhanced the cytotoxicit...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 1997/12/15, Vol.20(12), pp.1303-1306
Main Authors: FURUSAWA, Shinobu, NAKANO, Shinya, WU, Jianghong, SASAKI, Ken-ichi, TAKAYANAGI, Motoaki, TAKAYANAGI, Yoshio
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c633t-31d8dd5beaec788bae6f5525c4316e39e6dfbbc9039da6a0fa5b4d9faa0b64693
cites
container_end_page 1306
container_issue 12
container_start_page 1303
container_title Biological & pharmaceutical bulletin
container_volume 20
creator FURUSAWA, Shinobu
NAKANO, Shinya
WU, Jianghong
SASAKI, Ken-ichi
TAKAYANAGI, Motoaki
TAKAYANAGI, Yoshio
description The effect of the anti-tuberculosis drug rifampicin on pirarubicin activity was investigated in multidrug-resistant cells overexpressing P-glycoprotein. Rifampicin increased the sensitivity of pirarubicin to anthracycline-resistant mouse leukemic P388 cells and significantly enhanced the cytotoxicity and intracellular accumulation of pirarubicin in resistant cells, but had no effect in parent cells. By contrast, two other rifamycins, rifamycin B and SV, had no effect on pirarubicin accumulation in resistant cells. Rifampicin also enhanced pirarubicin-induced apoptosis and G2/M blockade on the cell cycle in resistant cells. These results show that rifampicin enhances the cytotoxic action of pirarubicin in resistant cells, at least partly via the inhibition of cellular pirarubicin efflux.
doi_str_mv 10.1248/bpb.20.1303
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1449170605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3120371961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c633t-31d8dd5beaec788bae6f5525c4316e39e6dfbbc9039da6a0fa5b4d9faa0b64693</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMoc35ceS0U9E46k-ZjzaUMp8JEEb0uJ2kyM7p2Jqmwf2_mym5yDrxPzgsPQlcET0jBynu1UZMi7RTTIzQmlE1zXhB-jMZYkjIXhJen6CyEFcZ4igs6QiPJWEmwHKO39y6aNjqIrmuzzmbvzoPvldOuzR50dL8ubrO0v_ZNdLXvl9mHCS5EaGM2M00TMrXNPpyF9Wb35wKdWGiCuRzmOfqaP37OnvPF29PL7GGRa0FpzCmpy7rmyoDR07JUYITlvOCaUSIMlUbUViktMZU1CMAWuGK1tABYCSYkPUc3-7sb3_30JsRq1fW-TZUVYUySKRaYJ-puT2nfheCNrTbercFvK4KrnbsquauKtCd3ib4ebvZqbeoDO8hK-e2QQ9DQWA-tduGAJeU4uU7YfI-tkqWlOeTgo9ON2VUSKel_bTG8u_4DoL_BV6alf9HGj8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449170605</pqid></control><display><type>article</type><title>Potentiation of Pirarubicin Activity in Multidrug Resistant Cells by Rifampicin</title><source>Full-Text Journals in Chemistry (Open access)</source><creator>FURUSAWA, Shinobu ; NAKANO, Shinya ; WU, Jianghong ; SASAKI, Ken-ichi ; TAKAYANAGI, Motoaki ; TAKAYANAGI, Yoshio</creator><creatorcontrib>FURUSAWA, Shinobu ; NAKANO, Shinya ; WU, Jianghong ; SASAKI, Ken-ichi ; TAKAYANAGI, Motoaki ; TAKAYANAGI, Yoshio</creatorcontrib><description>The effect of the anti-tuberculosis drug rifampicin on pirarubicin activity was investigated in multidrug-resistant cells overexpressing P-glycoprotein. Rifampicin increased the sensitivity of pirarubicin to anthracycline-resistant mouse leukemic P388 cells and significantly enhanced the cytotoxicity and intracellular accumulation of pirarubicin in resistant cells, but had no effect in parent cells. By contrast, two other rifamycins, rifamycin B and SV, had no effect on pirarubicin accumulation in resistant cells. Rifampicin also enhanced pirarubicin-induced apoptosis and G2/M blockade on the cell cycle in resistant cells. These results show that rifampicin enhances the cytotoxic action of pirarubicin in resistant cells, at least partly via the inhibition of cellular pirarubicin efflux.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.20.1303</identifier><identifier>PMID: 9448109</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>Animals ; Antibacterial agents ; Antibiotics, Antineoplastic - pharmacology ; Antibiotics, Antitubercular - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; apoptosis ; Apoptosis - drug effects ; Biological and medical sciences ; cell cycle ; Cell Cycle - drug effects ; cytotoxicity ; Doxorubicin - analogs &amp; derivatives ; Doxorubicin - pharmacology ; Drug Resistance, Multiple ; Drug Synergism ; Gene Expression Regulation, Neoplastic - drug effects ; Genes, MDR - drug effects ; Leukemia P388 - drug therapy ; Leukemia P388 - metabolism ; Medical sciences ; Mice ; multidrug-resistant cell ; Pharmacology. Drug treatments ; pirarubicin ; rifampicin ; Rifampin - pharmacology ; Tetrazolium Salts ; Thiazoles</subject><ispartof>Biological and Pharmaceutical Bulletin, 1997/12/15, Vol.20(12), pp.1303-1306</ispartof><rights>The Pharmaceutical Society of Japan</rights><rights>1998 INIST-CNRS</rights><rights>Copyright Japan Science and Technology Agency 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c633t-31d8dd5beaec788bae6f5525c4316e39e6dfbbc9039da6a0fa5b4d9faa0b64693</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2150615$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9448109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FURUSAWA, Shinobu</creatorcontrib><creatorcontrib>NAKANO, Shinya</creatorcontrib><creatorcontrib>WU, Jianghong</creatorcontrib><creatorcontrib>SASAKI, Ken-ichi</creatorcontrib><creatorcontrib>TAKAYANAGI, Motoaki</creatorcontrib><creatorcontrib>TAKAYANAGI, Yoshio</creatorcontrib><title>Potentiation of Pirarubicin Activity in Multidrug Resistant Cells by Rifampicin</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>The effect of the anti-tuberculosis drug rifampicin on pirarubicin activity was investigated in multidrug-resistant cells overexpressing P-glycoprotein. Rifampicin increased the sensitivity of pirarubicin to anthracycline-resistant mouse leukemic P388 cells and significantly enhanced the cytotoxicity and intracellular accumulation of pirarubicin in resistant cells, but had no effect in parent cells. By contrast, two other rifamycins, rifamycin B and SV, had no effect on pirarubicin accumulation in resistant cells. Rifampicin also enhanced pirarubicin-induced apoptosis and G2/M blockade on the cell cycle in resistant cells. These results show that rifampicin enhances the cytotoxic action of pirarubicin in resistant cells, at least partly via the inhibition of cellular pirarubicin efflux.</description><subject>Animals</subject><subject>Antibacterial agents</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>Antibiotics, Antitubercular - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>cell cycle</subject><subject>Cell Cycle - drug effects</subject><subject>cytotoxicity</subject><subject>Doxorubicin - analogs &amp; derivatives</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Synergism</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Genes, MDR - drug effects</subject><subject>Leukemia P388 - drug therapy</subject><subject>Leukemia P388 - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>multidrug-resistant cell</subject><subject>Pharmacology. Drug treatments</subject><subject>pirarubicin</subject><subject>rifampicin</subject><subject>Rifampin - pharmacology</subject><subject>Tetrazolium Salts</subject><subject>Thiazoles</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNo9kF1LwzAUhoMoc35ceS0U9E46k-ZjzaUMp8JEEb0uJ2kyM7p2Jqmwf2_mym5yDrxPzgsPQlcET0jBynu1UZMi7RTTIzQmlE1zXhB-jMZYkjIXhJen6CyEFcZ4igs6QiPJWEmwHKO39y6aNjqIrmuzzmbvzoPvldOuzR50dL8ubrO0v_ZNdLXvl9mHCS5EaGM2M00TMrXNPpyF9Wb35wKdWGiCuRzmOfqaP37OnvPF29PL7GGRa0FpzCmpy7rmyoDR07JUYITlvOCaUSIMlUbUViktMZU1CMAWuGK1tABYCSYkPUc3-7sb3_30JsRq1fW-TZUVYUySKRaYJ-puT2nfheCNrTbercFvK4KrnbsquauKtCd3ib4ebvZqbeoDO8hK-e2QQ9DQWA-tduGAJeU4uU7YfI-tkqWlOeTgo9ON2VUSKel_bTG8u_4DoL_BV6alf9HGj8Q</recordid><startdate>19971201</startdate><enddate>19971201</enddate><creator>FURUSAWA, Shinobu</creator><creator>NAKANO, Shinya</creator><creator>WU, Jianghong</creator><creator>SASAKI, Ken-ichi</creator><creator>TAKAYANAGI, Motoaki</creator><creator>TAKAYANAGI, Yoshio</creator><general>The Pharmaceutical Society of Japan</general><general>Maruzen</general><general>Japan Science and Technology Agency</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>19971201</creationdate><title>Potentiation of Pirarubicin Activity in Multidrug Resistant Cells by Rifampicin</title><author>FURUSAWA, Shinobu ; NAKANO, Shinya ; WU, Jianghong ; SASAKI, Ken-ichi ; TAKAYANAGI, Motoaki ; TAKAYANAGI, Yoshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c633t-31d8dd5beaec788bae6f5525c4316e39e6dfbbc9039da6a0fa5b4d9faa0b64693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Antibacterial agents</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>Antibiotics, Antitubercular - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>cell cycle</topic><topic>Cell Cycle - drug effects</topic><topic>cytotoxicity</topic><topic>Doxorubicin - analogs &amp; derivatives</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Synergism</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Genes, MDR - drug effects</topic><topic>Leukemia P388 - drug therapy</topic><topic>Leukemia P388 - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>multidrug-resistant cell</topic><topic>Pharmacology. Drug treatments</topic><topic>pirarubicin</topic><topic>rifampicin</topic><topic>Rifampin - pharmacology</topic><topic>Tetrazolium Salts</topic><topic>Thiazoles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FURUSAWA, Shinobu</creatorcontrib><creatorcontrib>NAKANO, Shinya</creatorcontrib><creatorcontrib>WU, Jianghong</creatorcontrib><creatorcontrib>SASAKI, Ken-ichi</creatorcontrib><creatorcontrib>TAKAYANAGI, Motoaki</creatorcontrib><creatorcontrib>TAKAYANAGI, Yoshio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FURUSAWA, Shinobu</au><au>NAKANO, Shinya</au><au>WU, Jianghong</au><au>SASAKI, Ken-ichi</au><au>TAKAYANAGI, Motoaki</au><au>TAKAYANAGI, Yoshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potentiation of Pirarubicin Activity in Multidrug Resistant Cells by Rifampicin</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>1997-12-01</date><risdate>1997</risdate><volume>20</volume><issue>12</issue><spage>1303</spage><epage>1306</epage><pages>1303-1306</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>The effect of the anti-tuberculosis drug rifampicin on pirarubicin activity was investigated in multidrug-resistant cells overexpressing P-glycoprotein. Rifampicin increased the sensitivity of pirarubicin to anthracycline-resistant mouse leukemic P388 cells and significantly enhanced the cytotoxicity and intracellular accumulation of pirarubicin in resistant cells, but had no effect in parent cells. By contrast, two other rifamycins, rifamycin B and SV, had no effect on pirarubicin accumulation in resistant cells. Rifampicin also enhanced pirarubicin-induced apoptosis and G2/M blockade on the cell cycle in resistant cells. These results show that rifampicin enhances the cytotoxic action of pirarubicin in resistant cells, at least partly via the inhibition of cellular pirarubicin efflux.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>9448109</pmid><doi>10.1248/bpb.20.1303</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 1997/12/15, Vol.20(12), pp.1303-1306
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_journals_1449170605
source Full-Text Journals in Chemistry (Open access)
subjects Animals
Antibacterial agents
Antibiotics, Antineoplastic - pharmacology
Antibiotics, Antitubercular - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
apoptosis
Apoptosis - drug effects
Biological and medical sciences
cell cycle
Cell Cycle - drug effects
cytotoxicity
Doxorubicin - analogs & derivatives
Doxorubicin - pharmacology
Drug Resistance, Multiple
Drug Synergism
Gene Expression Regulation, Neoplastic - drug effects
Genes, MDR - drug effects
Leukemia P388 - drug therapy
Leukemia P388 - metabolism
Medical sciences
Mice
multidrug-resistant cell
Pharmacology. Drug treatments
pirarubicin
rifampicin
Rifampin - pharmacology
Tetrazolium Salts
Thiazoles
title Potentiation of Pirarubicin Activity in Multidrug Resistant Cells by Rifampicin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A39%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potentiation%20of%20Pirarubicin%20Activity%20in%20Multidrug%20Resistant%20Cells%20by%20Rifampicin&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=FURUSAWA,%20Shinobu&rft.date=1997-12-01&rft.volume=20&rft.issue=12&rft.spage=1303&rft.epage=1306&rft.pages=1303-1306&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.20.1303&rft_dat=%3Cproquest_cross%3E3120371961%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c633t-31d8dd5beaec788bae6f5525c4316e39e6dfbbc9039da6a0fa5b4d9faa0b64693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1449170605&rft_id=info:pmid/9448109&rfr_iscdi=true